search icon
      blog search icon

      FSD Pharma Inc. (HUGE) stock is on a rise in premarket – Find out the reasons behind it! - Stocks Telegraph

      By Mahrukh Rehan

      Published on

      December 3, 2021

      11:59 AM UTC

      FSD Pharma Inc. (HUGE) stock is on a rise in premarket – Find out the reasons behind it! - Stocks Telegraph

      FSD Pharma Inc. (HUGE) saw an increase of 2.36% in the premarket after the announcement of Positive Effects of Lucid-MS. However, the last trading session closed at $1.27 with an increase of 8.55%.

      Positive Effects of Lucid-MS – New updates

      On 2nd December 2021, HUGE shared the preclinical data, accompanied by an explanation video, illustrating the potential disease-modifying benefits of Lucid-MS. It is the Company’s primary medication candidate for the treatment of multiple sclerosis. Lucid-MS is a patented neuroprotective novel chemical entity that alters protein citrullination and myelin structure. Furthermore, the Company has published a film outlining its pre-clinical achievements in addition to showing the Lucid-unique MS’s potential therapeutic usefulness.

      New Appointment by HUGE – See who’s this?

      On 16th November 2021, HUGE reported that Eleanor N. Fish has been appointed to the research and clinical advisory board. Dr. Fish is an experienced immunologist and member of the Government of Canada’s Expert Scientific Panel to the Chief Scientific Advisor. Lastly, he brings his valuable experience to HUGE that will help the business focus on developing FSD-PEA, and Lucid-MS.

      What’s next?

      Firstly, the company welcomes Dr. Eleanor Fish to the team. One of Eleanor’s main goals is to learn more about the onset and management of autoimmune disorders like multiple sclerosis and rheumatoid arthritis. Secondly, her long experience in translational research will tremendously benefit FSD’s existing and future pipelines. Thirdly, her skills and insights will be highly important as the company continues to progress the FSD-PEA and Lucid-MS initiatives.

      Agreement of HUGE and Covar Pharmaceuticals – More About it

      On 19th October 2021, HUGE stated that it has signed an agreement with Covar Pharmaceuticals Inc. This is a contract research and production services organization, to begin supplying research quantities of FSD’s therapeutic candidate. This agreement with Covar keeps us on track to finish extensive preclinical research and scale-up activities. Lastly, this might pave the way for the company to move Lucid-PSYCH from the bench to the clinic.

      About HUGE

      HUGE is a life sciences company with two fully-owned subsidiaries focused on developing a portfolio of varied therapeutic assets as well as new healthcare and biotech services. Moreover, it is a specialized biotech pharmaceutical R&D firm focusing on discovering uses for ultra micronized PEA, the company’s flagship ingredient, by down-regulating cytokines to induce an anti-inflammatory effect.

      More From Stocks telegraph